Literature DB >> 21957300

Epstein-Barr virus BamHI W repeat number limits EBNA2/EBNA-LP coexpression in newly infected B cells and the efficiency of B-cell transformation: a rationale for the multiple W repeats in wild-type virus strains.

Rosemary J Tierney1, Kuan-Yu Kao, Jasdeep K Nagra, Alan B Rickinson.   

Abstract

The genome of Epstein-Barr virus (EBV), a gammaherpesvirus with potent B-cell growth-transforming ability, contains multiple copies of a 3-kb BamHI W repeat sequence; each repeat carries (i) a promoter (Wp) that initiates transformation by driving EBNA-LP and EBNA2 expression and (ii) the W1W2 exons encoding the functionally active repeat domain of EBNA-LP. The W repeat copy number of a virus therefore influences two potential determinants of its transforming ability: the number of available Wp copies and the maximum size of the encoded EBNA-LP. Here, using recombinant EBVs, we show that optimal B-cell transformation requires a minimum of 5 W repeats (5W); the levels of transforming ability fall progressively with viruses carrying 4, 3, and 2 W repeats, as do the levels of Wp-initiated transcripts expressed early postinfection (p.i.), while viruses with 1 copy of the wild-type W repeat (1W) and 0W are completely nontransforming. We therefore suggest that genetic analyses of EBV transforming function should ensure that wild-type and mutant strains have equal numbers (ideally at least 5) of W copies if the analysis is not to be compromised. Attempts to enhance the transforming function of low-W-copy-number viruses, via the activity of helper EBV strains or by gene repair, suggested that the critical defect is not related to EBNA-LP size but to the failure to achieve sufficiently strong coexpression of EBNA-LP and EBNA2 early postinfection. We further show by the results of ex vivo assays that EBV strains in the blood of infected individuals typically have a mean of 5 to 8 W copies, consistent with the view that evolution has selected for viruses with an optimal transforming function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21957300      PMCID: PMC3209410          DOI: 10.1128/JVI.06059-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines.

Authors:  J Finke; M Rowe; B Kallin; I Ernberg; A Rosén; J Dillner; G Klein
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

2.  Multiple Epstein-Barr virus strains in patients with infectious mononucleosis: comparison of ex vivo samples with in vitro isolates by use of heteroduplex tracking assays.

Authors:  Rosemary J Tierney; Rachel Hood Edwards; Diane Sitki-Green; Deborah Croom-Carter; Sushmita Roy; Qing-Yun Yao; Nancy Raab-Traub; Alan B Rickinson
Journal:  J Infect Dis       Date:  2005-12-14       Impact factor: 5.226

3.  B-cell lines immortalized with an Epstein-Barr virus mutant lacking the Cp EBNA2 enhancer are biased toward utilization of the oriP-proximal EBNA gene promoter Wp1.

Authors:  L I Yoo; M Mooney; M T Puglielli; S H Speck
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

4.  An Epstein-Barr virus transcript from a latently infected, growth-transformed B-cell line encodes a highly repetitive polypeptide.

Authors:  S H Speck; A Pfitzner; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

5.  Clonal evolution of lymphoblastoid cell lines.

Authors:  Julie L Ryan; William K Kaufmann; Nancy Raab-Traub; Stephen E Oglesbee; Lisa A Carey; Margaret L Gulley
Journal:  Lab Invest       Date:  2006-10-02       Impact factor: 5.662

6.  Quantitative studies of Epstein-Barr virus-encoded microRNAs provide novel insights into their regulation.

Authors:  Richard Amoroso; Leah Fitzsimmons; Wendy A Thomas; Gemma L Kelly; Martin Rowe; Andrew I Bell
Journal:  J Virol       Date:  2010-11-10       Impact factor: 5.103

7.  Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification.

Authors:  Claire Shannon-Lowe; Emily Adland; Andrew I Bell; Henri-Jacques Delecluse; Alan B Rickinson; Martin Rowe
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

8.  Spliced RNA from the IR1-U2 region of Epstein-Barr virus: presence of an open reading frame for a repetitive polypeptide.

Authors:  M Bodescot; B Chambraud; P Farrell; M Perricaudet
Journal:  EMBO J       Date:  1984-08       Impact factor: 11.598

9.  EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus.

Authors:  A J Sinclair; I Palmero; G Peters; P J Farrell
Journal:  EMBO J       Date:  1994-07-15       Impact factor: 11.598

10.  An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link.

Authors:  Gemma L Kelly; Heather M Long; Julianna Stylianou; Wendy A Thomas; Alison Leese; Andrew I Bell; Georg W Bornkamm; Josef Mautner; Alan B Rickinson; Martin Rowe
Journal:  PLoS Pathog       Date:  2009-03-13       Impact factor: 6.823

View more
  19 in total

Review 1.  RNA families in Epstein-Barr virus.

Authors:  Walter N Moss; Nara Lee; Genaro Pimienta; Joan A Steitz
Journal:  RNA Biol       Date:  2013-12-20       Impact factor: 4.652

2.  The Epstein-Barr virus miR-BHRF1 microRNAs regulate viral gene expression in cis.

Authors:  Brigid Chiyoko Poling; Alexander M Price; Micah A Luftig; Bryan R Cullen
Journal:  Virology       Date:  2017-12       Impact factor: 3.616

3.  Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300.

Authors:  Chong Wang; Hufeng Zhou; Yong Xue; Jun Liang; Yohei Narita; Catherine Gerdt; Amy Y Zheng; Runsheng Jiang; Stephen Trudeau; Chih-Wen Peng; Benjamin E Gewurz; Bo Zhao
Journal:  J Virol       Date:  2018-04-13       Impact factor: 5.103

4.  The Epstein-Barr virus BamHI C promoter is not essential for B cell immortalization in vitro, but it greatly enhances B cell growth transformation.

Authors:  Rosemary J Tierney; Jasdeep Nagra; Martin Rowe; Andrew I Bell; Alan B Rickinson
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

5.  Repression of the proapoptotic cellular BIK/NBK gene by Epstein-Barr virus antagonizes transforming growth factor β1-induced B-cell apoptosis.

Authors:  Eva M Campion; Roya Hakimjavadi; Sinéad T Loughran; Susan Phelan; Sinéad M Smith; Brendan N D'Souza; Rosemary J Tierney; Andrew I Bell; Paul A Cahill; Dermot Walls
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

Review 6.  The many ways Epstein-Barr virus takes advantage of the RNA tool kit.

Authors:  Nara Lee
Journal:  RNA Biol       Date:  2021-01-30       Impact factor: 4.652

Review 7.  Viral noncoding RNAs: more surprises.

Authors:  Kazimierz T Tycowski; Yang Eric Guo; Nara Lee; Walter N Moss; Tenaya K Vallery; Mingyi Xie; Joan A Steitz
Journal:  Genes Dev       Date:  2015-03-15       Impact factor: 11.361

Review 8.  Epstein-barr virus sequence variation-biology and disease.

Authors:  Stelios Tzellos; Paul J Farrell
Journal:  Pathogens       Date:  2012-11-08

9.  Unexpected patterns of Epstein-Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mRNA.

Authors:  Rosemary J Tierney; Claire D Shannon-Lowe; Leah Fitzsimmons; Andrew I Bell; Martin Rowe
Journal:  Virology       Date:  2014-11-15       Impact factor: 3.616

10.  Genome-wide analyses of Epstein-Barr virus reveal conserved RNA structures and a novel stable intronic sequence RNA.

Authors:  Walter N Moss; Joan A Steitz
Journal:  BMC Genomics       Date:  2013-08-09       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.